Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × TAS 102 × regorafenib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 12 Carcinoma, Hepatocellular 4 Liver Neoplasms 3 TAS 102 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Colorectal Adenocarcinoma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Colonic Neoplasms 1 COVID-19 1 Advanced Colorectal Carcinoma 1

Interventions

regorafenib 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05993702 2023-08-15

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

China Medical University, China

Gastrointestinal

TAS 102

Data powered by HemOnc (CC BY 4.0) Colophon ⚡